Intrinsic Therapeutics, Inc., a medical device company focused on preventing reherniation and reoperation following lumbar discectomy, today announced the publication in JAMA Network Open of the five-year follow-up results from its landmark clinical trial demonstrating that the use of Barricaid following discectomy is superior to treating high-risk patients with discectomy alone.
|
BOSTON, Jan. 25, 2022 /PRNewswire/ -- Intrinsic Therapeutics Inc., a medical device company focused on preventing reherniation and reoperation following lumbar discectomy, today announced the publication in JAMA Network Open of the five-year follow-up results from its landmark clinical trial demonstrating that the use of Barricaid following discectomy is superior to treating high-risk patients with discectomy alone. High-risk discectomy patients treated with Barricaid are less likely to suffer reherniation/reoperation –Professor Thomé
The results of the 554-patient, randomized superiority trial indicate statistically significant reductions over the five-year period for both reherniation (41% reduction, p<0.001) and reoperation (29% reduction, p=0.03). This keystone publication adds to a robust body of evidence including 64 peer-reviewed manuscripts detailing eight distinct patient populations. "The five-year follow-up analysis makes it clear that lumbar discectomies are not as benign as we originally thought. The JAMA study results conclusively show high-risk lumbar discectomy patients treated with Barricaid are less likely to suffer reherniation and reoperation than those patients treated with discectomy alone," said Professor Claudius Thomé, Head of Neurosurgery at the University of Innsbruck, Austria, and Principal Investigator of this trial. In addition, the rates of serious adverse events related to either the implant and/or procedure were significantly lower in the patients treated with Barricaid (12.0% vs 20.5%) (P=0.008), indicating that use of the Barricaid lowers the incidence of complications leading to costly hospital readmissions. "Not surprisingly, patients who have operations for reherniation don't generally experience the same pain and functional improvement as patients not requiring additional surgery," explained Dr. Pierce Nunley, Director of the Spine Institute of Louisiana. "With the proven reduction in reoperation, this large, multicenter study reaffirms and compliments a large body of published evidence supporting Barricaid's medical and economic benefits." Link to full article: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786990 About herniation and lumbar discectomy: Explanation video: https://bit.ly/3tU80bk Radiating pain in the leg is often caused by a herniated lumbar disc compressing the nerve. Since this condition mostly affects a relatively young, active patient population, the social and economic consequences resulting from disability and absenteeism from work are significant. Surgery for a herniated disc is generally only considered when conservative treatment options have failed. Many patients undergoing a discectomy surgery for a herniated lumbar disc are at high risk of reherniation and reoperation. With nearly 500,000 discectomies performed annually in the United States alone, this poses a significant problem not only for the patients affected, but for society as a whole. About Intrinsic Therapeutics Barricaid is a registered trademark of Intrinsic Therapeutics, Inc. Media contact person:
SOURCE Intrinsic Therapeutics, Inc. |
View original content to download multimedia:
